Led · Series B · May 2026

RADAR provides a vertically integrated system of overhead RFID sensors, software, and analytics that captures a full inventory snapshot every eight seconds and delivers roughly 99% item-level inventory accuracy. Its platform converts continuous location signals into operational actions such as automated replenishment alerts, omnichannel fulfillment routing, loss-prevention triggers, and merchandising intelligence. The company is deployed across more than 1,400 stores with major U.S. retailers including American Eagle Outfitters and Old Navy and processes more than 100 billion item-level events per day. RADAR positions its dataset as a foundation for forecasting demand, optimizing assortments, and understanding in-store customer interactions. The company plans to advance sensor hardware, expand AI capabilities, pursue autonomous checkout, and grow internationally while scaling operations under new CFO Abi Viswanathan.

Participated · Series C · Sep 2025

SafeHeal SAS, together with its U.S. subsidiary SafeHeal Inc., designs and develops Colovac, a flexible endoluminal bypass sheath intended to shield the anastomotic site from fecal matter following colorectal surgery. The device remains in place for roughly 10 days and is later removed endoscopically, sparing patients a second surgical intervention and the lifestyle burdens of an ostomy bag. Colovac is currently limited to investigational use in the United States under an IDE study, while commercialization efforts are focused on the European Union. The newly raised capital will accelerate the U.S. pivotal IDE trial and fund EU commercial launch preparations. SafeHeal’s Series C round was initially €35 million and has now been extended, demonstrating strong investor interest. Although the company has not disclosed revenue or user metrics, its financing momentum underscores market confidence in the potential clinical and economic benefits of Colovac.

Participated · Series C · Dec 2024

Capstan Medical is developing a first-of-its-kind catheter-based robotic delivery platform and a suite of next-generation heart valve implants to expand percutaneous treatment options. The company’s solution targets mitral and tricuspid valve disease and aims to overcome limitations of open-heart surgery and existing catheter-based options. Capstan has grown to over 75 employees across engineering, operations, clinical, and regulatory. Since its founding in 2020, the team has focused on combining novel implants, advanced catheter technology, and robotics to treat a broader set of patients. With new funding, the company plans to continue expanded clinical and development work and advance toward upcoming pivotal trials. Capstan Medical is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform for minimally invasive treatment of heart valve disease. The company’s catheter-based approach enables procedures through a small groin incision without stopping the heart or opening the chest, shortening recovery from months to weeks. Capstan plans to use the new funding to expand engineering, clinical development, and operations teams and to progress the technology toward first human use. The company is led by CEO Maggie Nixon and CTO Dan Wallace. Capstan was founded in 2020 and is based in Santa Cruz, CA. The firm emphasizes treating even very sick patients with less invasive catheter-based techniques.

Participated · Series D · Jun 2024

Osteal Therapeutics is a clinical-stage biopharmaceutical company developing novel combination drug/device therapies to treat orthopedic infections and their consequences. Its lead candidate, VT-X7, is a seven-day vancomycin and tobramycin irrigation drug/device designed to deliver antibiotics directly to the joint space to treat periprosthetic joint infection (PJI). In clinical studies, 100% of patients were treated and received a new permanent joint prosthesis in seven days with more than 90% remaining infection-free after one year. VT-X7 has been evaluated in two multicenter randomized controlled trials, APEX and APEX-2; APEX met its primary endpoint in 2023 and APEX-2 recently met its primary endpoint and will be completed in late 2024. The FDA has granted VT-X7 Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations, and the company expects to seek approval upon APEX-2 completion. Osteal leverages locally delivered, concentrated antimicrobials and repurposes approved drugs for new local-delivery routes to address biofilm-driven musculoskeletal infections. Osteal Therapeutics is a Dallas, TX-based clinical-stage biopharmaceutical company developing musculoskeletal therapeutics to treat orthopedic infections and their consequences. Its lead candidate, VT-X7, is a locally delivered antimicrobial in Phase 2 development aimed at treating periprosthetic joint infections (PJI). The company leverages concentrated, locally delivered antimicrobials to combat bacterial biofilms while minimizing off-target tissue exposure and adverse effects. Osteal employs a low-risk development approach by repurposing approved drugs with known safety and efficacy profiles for new routes of local delivery. It recently closed a $23M Series C financing to fund its next steps. Proceeds will support an NDA submission to the FDA and accelerate preparation for VT-X7's commercial launch; the company is led by CEO and President David Thompson. Osteal Therapeutics is a clinical-stage biopharmaceutical company creating a new category of combination therapies to treat musculoskeletal infections by delivering concentrated, locally applied antimicrobials to target biofilms. Its lead candidate, VT-X7, is a drug/device combination (vancomycin HCl and tobramycin sulfate for irrigation) designed as a seven-day therapy to deliver antibiotics directly to the joint space and surrounding tissue to treat chronic periprosthetic joint infection (PJI). VT-X7 completed an open-label Phase 2 trial in which 100% of VT-X7 patients were treated and received a new permanent joint prosthesis in seven days and 93% remained infection-free at one year. The company is currently enrolling APEX, a randomized controlled study of VT-X7 versus the current standard of care (two-stage exchange arthroplasty). The FDA has granted VT-X7 Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations. Osteal plans to use new capital to advance VT-X7 into later-stage clinical trials and to fund additional research programs.